Skip to main content

Table 1 Parasite load reduction (percentage) of each drug within 24 h after the first day of treatment with the trioxaquine, artesunate, 4,7-dichloroquinoline and quinine against Plasmodium berghei ANKA in C57BL/6 mice using the established infection test

From: Efficacy and safety evaluation of a novel trioxaquine in the management of cerebral malaria in a mouse model

Drug/dosage (mg/kg)

Day 8 pi mean parasitaemia ± SD

24 h post-treatment parasitaemia ± SD

48 h post-treatment parasitaemia ± SD

Percentage parasitaemia clearance in 24 h

Recrudescence

Trioxaquine

 25

11.73 ± 0.06

0.42 ± 0.11

0.00

96.4

Not observed

 12.5

11.69 ± 0.03

1.56 ± 0.08

0.00

86.6

Not observed

Artesunate

 12.5

11.75 ± 0.05

1.77 ± 0.04

0.00

84.8

Observed

4,7-Dichloroquinoline

 12.5

11.55 ± 0.07

11.45 ± 0.04

11.41 ± 0.02

1.89

ND

Quinine

 60

11.65 ± 0.03

11.79 ± 0.01

6.52 ± 0.02

1.03

Observed

Untreated control

11.67 ± 0.05

11.83 ± 0.04

100% Mortality recorded

–

–

  1. Treatment was initiated on day 8 post-infection. Drugs administered iv twice a day, for 3 days, within 12-h intervals and parasitaemia data before and 24 h post-treatment compared using paired Student t test (p < 0.05). Parasitaemia levels were similar in all the experimental groups before treatment (ANOVA, p >0.05)
  2. ND not determined (100% mortality occurred)
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us